c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer

Journal of Immunotherapy

Volumn 23, Issue 1, 2000, Pages 104-114

  Koukourakis, Michael I ^a,d   Giatromanolaki, Alexandra ^a   Guddo, Francesca ^b   Kaklamanis, Loukas ^c   Vignola, Maurizio ^b   Kakolyris, Stelios ^b   Turley, Hellen ^c   Georgoulias, Vassilios ^a   Bonsignore, Giovanni ^b   Gatter, Kevin C ^c   Harris, Adrian L ^c  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^b Centro Nazionale delle Ricerche   (Italy)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Tumour and Angiogenesis Research Group Iraklion   (Greece)

Author keywords

C erbB 2 ; Episialin; HLA class I; Lung cancer; Platelet endothelial cell adhesion molecule 1

Indexed keywords

ANGIOGENIC FACTOR; CARRIER PROTEIN; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPISIALIN; GLYCOPROTEIN; HLA ANTIGEN CLASS 1; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

AGED; CA-15-3 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVORS;

EID: 0033964654     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200001000-00013     Document Type: Article

References (59)

1. Bodmer W. The HLA system: structure and function. J Clin Pathol 1987;40:948-58.
2. Spies T, Gerundolo V, Collona M, et al. Presentation of endogenous viral antigen dependent on putative peptide transporter heterodimer. Nature 1992;355:644-9.
3. Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI. c-myc down-regulates class I HLA expression in human melanomas. EMBO J 1988;7:1023-9.
4. Rosa F, Fellous M, Dron M, Tovey M, Revel M. Presence of an abnormal b2-microglobulin mRNA in Daudi cells: induction by interferon. Immunogenetics 1983;17:125-31.
5. Momburg F, Koch S. Selective loss of b2-microglobulin mRNA in human colon carcinoma. J Exp Med 1989;169:309-14.
6. Spies T, DeMars R. Restored expression of major histocompatibility class-I molecules by gene transfer of a putative peptide transporter. Nature 1991;351:323-5.
7. Vanky F, Stuber G, Rotstein S, Klein E. Auto-tumor recognition following in vitro induction of MHC antigen expression on solid tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells. Cancer Immunol Immunother 1989;28:17-21.
8. Pandolfi F, Boyle LA, Trentin L, et al. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991;51:3164-70.
9. Darrow TL, Slingluff CL, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor specific cytotoxic T lymphocytes: evidence of shared tumor antigens. J Immunol 1989;142:3329-35.
10. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
11. Kern JA, Slebos RJC, Top B, et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994;93:516-20.
12. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;27: 1372-5.
13. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody Immunity to her-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
14. Yoshino I, Goedegebuure PS, Peoples GE, et al. Her-2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-90.
15. Gedde-Dahl T, Possum B, Eriksen JA, Thorsby E, Gaudernack G. T-cell clones specific for p21 Ras-derived peptides: characterisation of their fine specificity and HLA restriction. Eur J Immunol 1993;23:754-60.
16. Houbiers JGA, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur J Immunol 1993;23:2072-6.
17. Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34:197-206.
18. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-2.
19. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific major histocompatibility complex recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159-64.
20. Mountain CF. A new international staging system for lung cancer. Chest 1986;89(Suppl):225-31.
21. Korkolopoulou-P, Kaklamanis-L, Pezzella-F, Harris-AL, GatterKC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996;73(2):148-53.
22. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of tap 1 transport protein and MHC-class I molecules in metastatic compared to primary breast cancer. Cancer Res 1995; 55:5191-4.
23. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 1996;16:3819-26.
24. Harpole DH, Hendon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995;55:51-6.
25. Kay EW, Barry Walsh CJ, Curran B, Leader M. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994;47: 816-22.
26. Veale D, Aschroft T, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987; 55:513-16.
27. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-71.
28. McLaren R, Kuzu I, Dunnill M, et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735-8.
29. Pezzella F, Micklem K, Turley H, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 1994;47:592-6.
30. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non small cell lung carcinoma. N Engl J Med 1993;329:690-4.
31. Tungekar MF, Gatter KC, Dunnil MS, Mason DY. Ki-67 immunostaining and survival in operable lung cancer. Histopathology 1991;19:545-50.
32. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996;179:80-8.
33. Giatromanolaki A, Koukourakis M, Thedossiou D, et al. Comparative evaluation of angiogenesis assesment with anti-factor VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 1997;3:2493-2500.
34. Koukourakis MI, Giatromanolaki A, O'Byrne K, et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small cell lung cancer. Br J Cancer 1997;4:477-81.
35. Koukourakis M, Giatromanolaki A, Kakolyris S, et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non small cell lung cancer and impact on tumour neoangiogenesis and survival. Br J Cancer 1998;77:1696-1703.
36. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4: 3017-24.
37. Passlick B, Pantel K, Kubuschok B, et al. Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 1996;32A(1):141-5.
38. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 1994;30:376-81.
39. Harpole DH, Hendon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995;55:51-6.
40. Howcroft TK, Richardson JC, Singer DS. MHC class I gene expression is negatively regulated by the proto-oncogene, c-jun. EMBO J 1993;12:3163-9.
41. Peltenburg LT, Dee R, Schrier PI, Downregulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A. Nucleic Acids Res 1993;21:1179-85.
42. Yamit-Hezi A, Plaksin D, Eisenbach L. c-fos and c-jun overexpression in malignant cells reduces their tumorigenic and metastatic potential, and affects their MHC class I gene expression. Oncogene 1994;9:1065-79.
43. Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92: 432-6.
44. Fisk B, Savary C, Hudson JM, et al. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother 1995;18:197-209.
45. Ochiai A, Akimoto S, Kanai Y, et al. C-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 1994;205:73-8.
46. de-Porter CR, Eeckhout I, Schelfhout AM, Geerts ML, Roels HJ. Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast. Histopathology 1994;24:349-56.
47. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7:565-77.
48. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens-J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129: 255-65.
49. Bernstein JJ, Anagnostopoulos AV, Hattwick EA, Laws ER Jr. Human specific c-neu proto-oncogene protein overexpression in human malignant astrocytomas before and after xenografting. J Neurosurg 1993;78:240-51.
50. Geldhof AB, VandenDriessche T, Oigpdenakker G, De Baetselier P. Introduction of the interferon gamma gene into mouse T lymphoma cells with low MHC class I-expression results in selective induction of H-2Dk and concomitant enhanced metastasis. Cancer Immunol Immunother 1996;42:329-38.
51. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55:4140.
52. Pupa SM, Bufalino R, Invernizzi AM, et al. Macrophage infiltrate and prognosis in c-erbB-2 overexpressing breast carcinomas. J Clin Oncol 1996;14:85-94.
53. Elliot T, Cerundolo V, Elvin J, Townsend A. Peptide induced conformational change of a class I heavy chain. Nature 1991;351: 402-6.
54. Delval M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecule depends on its neighbouring residues in the protein. Cell 1991;66:1145-53.
55. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7:565-77.
56. Demeure CE, Byun DG, Yang LP, Vezzio N, Delespesse G. CD31 (PECAM-1) is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells. Immunology 1996;88:110-5.
57. Piali L, Hammel P, Uherek C, et al. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 1995;130:451-60.
58. Wakelin MW, Sanz MJ, Dewar A, et al. An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from messenteric microvessels in vivo by blocking the passage through the basement membrane. J Exp Med 1996;184: 229-39.
59. Jabrane-Ferrat N, Faille A, Loiseau P, et al. Effect of gamma interferon on HLA class I and II transcription and protein expression in human breast adenocarcinoma cell lines. Int J Cancer 1990; 45:1169-76.